Chikungunya virus outbreak kills six on France's Réunion Island
The deaths, between 10 and 30 March, were of people aged over 70 with underlying health conditions, the latest bulletin from France's public health agency, Santé Publique France said.
The agency also said that several other deaths were being investigated to determine whether the virus was a factor.
An epidemic was declared on Réunion Island on 13 January, following a surge in cases that began in August 2024.
Health officials linked the outbreak to rising mosquito numbers during the summer and low immunity levels in the island's population of around 900,000.
Health officials say the situation remains serious, despite some early signs of improvement.
Reunion Island launches emergency health plan amid chikungunya epidemic
Chikungunya is spread by Aedes mosquitoes and causes fever, a rash and joint pain. It can be particularly dangerous for older people, pregnant women, babies and those with chronic illnesses.
In the week from 31 March to 6 April, a total of 4,913 new cases were confirmed, down from nearly 6,300 the week before.
Read more on RFI EnglishRead also:Cyclone death toll rises to four on ravaged French islandTwo die from chikungunya as virus spreads on France's Reunion IslandRéunion Island company revives ancient fermentation technique to boost health
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
11 hours ago
- Business Wire
CARMAT Announces the Initiation of a Call for Public Tenders (Buyers or Investors) as Part of the Receivership Procedure
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the initiation of a call for public tenders (buyers or investors) 1 as part of the receivership procedure 2 opened on July 1, 2025. A notice will be published in 'Les Echos' French newspaper by the judiciary administrator appointed by the Versailles Economic Affairs Court 3 (AJRS – Maître Philippe Jeannerot), on July 4, 2025. The Notice will however be available in the digital version of the newspaper as early as July 3, 2025 in the evening. People interested and willing to take part in the call for public tenders are invited to get in touch with Mr Valentin Laigneau (AJRS): It is reminded that CARMAT's operations carry on during the observation period, and that CARMAT continues to endeavor to provide continuous support to patients who currently benefit from its Aeson® artificial heart. Press releases will continue to be issued regularly as the Company's situation evolves and the proceedings progress. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company is currently placed in receivership (opened on July 1, 2025) and is facing a very high risk of default, including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA). 1 « Appel d'Offres (recherche de repreneurs ou d'investisseurs ») 2 « Redressement judiciaire » 3 « Tribunal des Affaires Economiques de Versailles (France) »
Miami Herald
14 hours ago
- Miami Herald
As Florida mosquito season peaks, officials brace for new normal of dengue cases
As summer ushers in peak mosquito season, health and vector control officials are bracing for the possibility of another year of historic rates of dengue. And with climate change, the lack of an effective vaccine, and federal research cuts, they worry the disease will become endemic to a larger swath of North America. About 3,700 new dengue infections were reported last year in the contiguous United States, up from about 2,050 in 2023, according to the Centers for Disease Control and Prevention. All of last year's cases were acquired abroad, except for 105 cases contracted in Florida, California or Texas. The CDC issued a health alert in March warning of the ongoing risk of dengue infection. 'I think dengue is here with us to stay,' said infectious disease specialist Michael Ben-Aderet, associate medical director of hospital epidemiology at Cedars-Sinai in Los Angeles, about dengue becoming a new normal in the U.S. 'These mosquitoes aren't going anywhere.' Dengue is endemic — a label health officials assign when diseases appear consistently in a region — in many warmer parts of the world, including Latin America, India and Southeast Asia. Dengue cases increased markedly last year in many of those places, especially in Central and South America. The disease, which can spread when people are bitten by infected Aedes mosquitoes, was not common in the contiguous United States for much of the last century. Today, most locally acquired (meaning unrelated to travel) dengue cases in the U.S. happen in Puerto Rico, which saw a sharp increase in 2024, triggering a local public health emergency. Most people who contract dengue don't get sick. But in some people symptoms are severe: bleeding from the nose or mouth, intense stomach pain, vomiting, and swelling. Occasionally, dengue causes death. MORE: Dengue fever on the rise. What to know about the mosquito-borne illness in Florida California offers a case study in how dengue is spreading in the U.S. The Aedes aegypti and Aedes albopictus mosquitoes that transmit dengue weren't known to be in the state 25 years ago. They are now found in 25 counties and more than 400 cities and unincorporated communities, mostly in Southern California and the Central Valley. The spread of the mosquitoes is concerning because their presence increases the likelihood of disease transmission, said Steve Abshier, president of the Mosquito and Vector Control Association of California. From 2016 through 2022, there were an average of 136 new dengue cases a year in California, each case most likely brought to the state by someone who had traveled and been infected elsewhere. In 2023, there were about 250 new cases, including two acquired locally. In 2024, California saw 725 new dengue cases, including 18 acquired locally, state data shows. Climate change could contribute to growth in the Aedes mosquitoes' population, Ben-Aderet said. These mosquitoes survive best in warm urban areas, often biting during the daytime. Locally acquired infections often occur when someone catches dengue during travel, then comes home and is bitten by an Aedes mosquito that bites and infects another person. 'They've just been spreading like wildfire throughout California,' Ben-Aderet said. Dengue presents a challenge to the many primary care doctors who have never seen it. Ben-Aderet said doctors who suspect dengue should obtain a detailed travel history from their patients, but confirming the diagnosis is not always quick. 'There's no easy test for it,' he said. 'The only test that we have for dengue is antibody tests.' He added that 'most labs probably aren't doing it commercially, so it's usually like a send-out test from most labs. So you really have to suspect someone has dengue.' Best practices for avoiding dengue include eliminating any standing pools of water on a property — even small pools — and using mosquito repellent, Abshier said. Limiting activity at dusk and dawn, when mosquitoes bite most often, can also help. Efforts to combat dengue in California became even more complicated this year after wildfires ripped through Los Angeles. The fires occurred in a hot spot for mosquito-borne illnesses. San Gabriel Valley Mosquito and Vector Control District officials have worked for months to treat more than 1,400 unmaintained swimming pools left in the wake of fire, removing potential breeding grounds for mosquitoes. San Gabriel vector control officials have used local and state resources to treat the pools, said district spokesperson Anais Medina Diaz. They have applied for reimbursement from the Federal Emergency Management Agency, which has not historically paid for vector control efforts following wildfires. In California, vector control agencies are often primarily funded by local taxes and fees on property owners. Some officials are pursuing the novel method of releasing sterilized Aedes mosquitoes to reduce the problem. That may prove effective, but deploying the method in a large number of areas would be costly and would require a massive effort at the state level, Abshier said. Meanwhile, the federal government is pulling back on interventions: Several outlets have reported that the National Institutes of Health will stop funding new climate change-related research, which could include work on dengue. This year, reported rates of dengue in much of the Americas have declined significantly from 2024. But the trend in the United States likely won't be clear until later in the year, after the summer mosquito season ends. Health and vector control researchers aren't sure how bad it will get in California. Some say there may be limited outbreaks, while others predict dengue could get much worse. Sujan Shresta, a professor and infectious disease researcher at the La Jolla Institute for Immunology, said other places, like Nepal, experienced relatively few cases of dengue in the recent past but now regularly see large outbreaks. There is a vaccine for children, but it faces discontinuation from a lack of global demand. Two other dengue vaccines are unavailable in the United States. Shresta's lab is hard at work on an effective, safe vaccine for dengue. She hopes to release results from animal testing in a year or so; if the results are positive, human trials could be possible in about two years. 'If there's no good vaccine, no good antivirals, this will be a dengue-endemic country,' she said. Phillip Reese is a data reporting specialist and an associate professor of journalism at California State University-Sacramento. This article was produced by KFF Health News, which publishes California Healthline, an editorially independent service of the California Health Care Foundation. KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.
Yahoo
14 hours ago
- Yahoo
Venus Williams Opens Up About Her 30-Year Fibroids Journey
Collage: Self; Source images: Venus Williams, Paper Whistle, anlomaja With four Olympic gold medals, seven Grand Slam titles, and over $42 million in prize money under her belt, Venus Williams is one of the most successful athletes in history. But behind closed doors, she has been fighting a painful battle for decades that far too many Black women know well: uterine fibroids. 'I remember playing my first French open, at the time I was 16,' Williams shares with SELF over Zoom from her home in Florida. 'Before the second round, I was waiting for my match and I was just hugging the toilet bowl. I was losing my lunch over period pains.' But who would have guessed? Just moments prior—adorned in an iconic silver getup, her braids covered in white beads—Williams was on her A-game, defeating Japan's Naoko Sawamatsu in the first round of the 1997 tournament. 'Those are the things behind the scenes you don't see,' she says. For as long as she can remember, the now 45-year-old tennis star has had painful periods—one of the most common symptoms among women who suffer from fibroids, or noncancerous growths in or on the uterus that can cause heavy menstruation and intense discomfort. Yet Williams can't even recall getting a formal diagnosis. 'I think I just kind of diagnosed myself,' she shares. While her gynecologist eventually confirmed that she did, indeed, have fibroids in 2016, her pain was treated as a routine side effect of the condition. 'They would tell me we'll just watch it,' she shares. The only treatment option made available to her was a hysterectomy, and Williams held off. Williams was never offered any other clear pathway to finding relief—even as the agony from her fibroids was getting worse. By her mid-30s, she says, she was taking prescription pain killers to find some sort of ease. 'I had those pills with me everywhere,' Williams says. 'I could never be caught anywhere without my pain pills. Getting caught in that kind of pain is a disaster.' Beyond the physical pain from her fibroids, the mental anguish took a toll as well. Williams's periods became so heavy that anywhere she went, she would have to pack extra pads, tampons, fresh underwear, and a change of clothes. 'It was always an 'accident run' to the bathroom,' she remembers. 'At times you're like, Oh my God, I have to clean my pants. You have to take them off at a restaurant, wash them out—crazy stuff. That's not normal.' By 2024, Williams knew it was time to advocate for herself—something her previous doctor never seemed to do, although she shares she has no interest in placing blame anywhere. The women's health space was revolutionizing: New models were popping up that made care more accessible and inviting. (Think easy-to-navigate millennial-friendly women's medical startups like Tia and Midi.) One day while scrolling Instagram, Williams saw an ad for a fibroid clinic that detailed promising treatment options for women just like her, which made her realize that she had options. The times were changing. Eventually Williams found Taraneh Shirazian, MD, a board-certified gynecologist and director of the Center for Fibroid Care at NYU Langone. 'It was amazing for me because I was able to talk to someone who felt confident that they could treat me,' Williams says. Unlike many medical professionals in the US, Dr. Shirazian takes a holistic, personalized approach to fibroid treatment, viewing it as a chronic ailment that needs continuous care rather than something to vaguely monitor—or, on the other hand, treat with a one-and-done surgery. As part of her model, Dr. Shirazian also looks at how the condition affects other aspects of a patient's life, like fertility and general discomfort. For Williams, this led to a more comprehensive diagnosis: The athlete learned that she also had an adenomyoma, which meant in addition to her fibroids, the lining of her uterus was growing into her uterine wall. 'I was the first person to ever tell her [of the condition],' Dr. Shirazian tells SELF. 'I could tell when I said it that she never heard about the adenomyoma before, and when you hear something for the first time, you need time to really understand it, think about it, and come to terms with what you want to do.' Williams shares that while it felt good to be informed, she left the office terrified. 'For the first time in my life ever, [I thought,] Why me? Why do I have to [go through] this?' There were a few courses of treatment Williams could take, according to Dr. Shirazian: Uterine-sparing surgery, which would remove the fibroids but leave the uterus in place, would be the best option, though radiofrequency treatments could also help shrink the fibroids and relieve some pain. Though trepidatious, Williams opted for the surgery. 'Surgery completely removes disease,' the gynecologist explains. '[Venus] had been suffering for all that time. Obviously we always need to be monitoring, but given her personal history, her symptoms, and again, just with that eye on what would be good for her specifically, we arrived at that conclusion.' 'I just remember I went into the [operating room] and I started to get a little afraid again,' Williams recalls. '[Dr. Shirazian] held my hand and I was out. I don't remember much after that, but I remember she held my hand, and that meant so much.' The surgery took place in July 2024. It was a success, and Williams had no complications. Within a day or two, she was up and moving around. By day 30 of her post-op recovery, she fully felt like herself again—just without the excessive bleeding and pain. At last, after decades of suffering, Williams felt relief—within just three months of meeting Dr. Shirazian. 'I went through a lot, and you would imagine that I would have access to the best health care—and I did. But I still didn't have the best health care [until I went to NYU],' Williams shares. With anywhere from 40% to 80% of people with a uterus being likely to develop fibroids by 50—with Black women three times more likely to get them, and get them at a younger age compared to white women—Williams's hope is that sharing her story will encourage others to seek the help they may not realize they need. 'As a patient, you have to be your own advocate,' she explains, noting the serious flaws in the US healthcare system. 'If you don't know what's wrong with you in the first place, you never even know to bring it up.' But being aware of what's happening with your body and having the ability to advocate for yourself, especially as a Black woman, is only half the battle. A 2022 Pew Research Center study found that 55% of Black Americans 'have had negative experiences with doctors.' A 2024 study found that 58% of Black women, in comparison to 44% of Black men, believe that the country's health care system was designed to hold them back. Of course, this is all happening in the context of our medical establishment's racist history: For many years, the US carried out nonconsensual medical experiments on African Americans, which may also lead to lingering distrust today. Dr. Shirazian hopes to remedy as much of this as she can through working with grassroots organizations in the Black community. The MD currently partners with The White Dress Project, a patient advocacy group that raises awareness about uterine fibroids through education and research. 'They share information on doctors and hospitals to go to who are giving good services and good care [throughout the country],' Dr. Shirazian says. By being one of the few MDs in the country taking a true holistic approach to fibroid treatment—from providing personalized care to bridging the knowledge gap by working with local organizations—Dr. Shirazian hopes that other medical facilities will follow her lead. 'Sometimes that's how you get bigger institutions to sort of take notice,' she shares. '[Our approach is] innovative and revolutionary, and whatever we can say that helps [other doctors] understand that these are priorities, that's my goal.' It's now been a year since Williams's surgery. She is happy and fully free from the pain that took over her life for nearly 30 years. But most of all, she wants to make sure this isn't any other woman's story. 'Make sure you have a doctor that believes in you and that you believe in [them], that's important,' she says. 'You don't have to settle at all.' Related: Jennie Garth on Having Hip Replacements at 48 and 52: 'I No Longer Want to Hide Things' Jamie-Lynn Sigler Was in Denial of Her MS for 15 Years: 'If I Didn't Talk About It, It Wasn't Real' What to Do If Your Doctor Isn't Taking Your Period Pain Seriously Get more of SELF's great service journalism delivered right to your inbox. Originally Appeared on Self
